07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

IV TRC105: Phase II data

An open-label, U.S. Phase II compassionate use trial in a single patient with choriocarcinoma showed that once-weekly 10 mg/kg IV TRC105 plus 10 mg/kg IV Avastin bevacizumab every 2 weeks led to an ongoing...
00:55 , Sep 19, 2015 |  BC Extra  |  Clinical News

Tracon gains on single patient study

Tracon Pharmaceuticals Inc. (NASDAQ:TCON) gained $4.23 (36%) to $15.96 after it said IV TRC105 generated a sustained complete response in a single-patient Phase II compassionate use study to treat choriocarcinoma. Results were presented at the...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Company News

Strand Life Sciences Pvt. Ltd., HealthCare Global Enterprises Ltd. deal

Strand partnered with HealthCare Global Enterprises (HCG) to provide personalized genomics services for oncology to hospitals and diagnostic labs worldwide on a fee-for-service basis. Strand said the partnership will use Strand's StrandOmics technology and its...
08:00 , Feb 25, 2013 |  BC Week In Review  |  Company News

NexGen Medical Systems Inc, Stem Cell Therapeutics deal

Stem Cell Therapeutics and NexGen will form a JV called ReNeu Inc. (Calgary, Alberta) to develop a direct-to-brain administration technique for stem-cell stimulating compounds from Stem Cell Therapeutics. Stem Cell Therapeutics said it will own...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Clinical News

BHCG-VAC: Phase II discontinued

Celldex disclosed in its 2Q11 earnings that in June it discontinued an open-label, U.S. Phase II trial comparing neoadjuvant therapy with CDX-1307 plus cisplatin and gemcitabine vs. cisplatin and gemcitabine alone prior to surgical resection...
07:00 , May 9, 2011 |  BC Week In Review  |  Clinical News

NTx-428: Phase IIa started

Stem Cell Therapeutics said investigators began an open-label, Canadian Phase IIa trial to evaluate NTx-428 in 10 patients. Stem Cell Therapeutics Corp. (TSX-V:SSS), Calgary, Alberta   Product: NTx-428   Business: Inflammation   Molecular target: NA   Description: Combination...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Clinical News

NTx-265: Additional Phase IIb data

A subset analysis of patients who received occupational therapy (OT) (about 25%) in the double-blind, international Phase IIb REGENESIS trial in 96 patients showed that NTx-265 significantly reduced NIHSS score from baseline vs. placebo (8.6...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Company News

Stem Cell Therapeutics neurology news

Stem Cell terminated the employment contracts of its four senior officers and expects additional headcount reductions to cut costs after further analysis of the Phase IIb REGENESIS trial of NTx-265 to treat stroke did...
07:00 , May 31, 2010 |  BC Week In Review  |  Clinical News

NTx-265: Phase IIb data

Top-line data from the double-blind, international Phase IIb REGENESIS trial in 96 patients showed that NTx-265 missed the primary endpoint of a significantly greater absolute change in NIHSS score from baseline vs. placebo at day...
07:00 , May 24, 2010 |  BC Week In Review  |  Clinical News

CDX-1307: Phase II started

Celldex began a U.S. Phase II trial in about 60 patients with newly diagnosed hCG-beta expressing muscle-invasive bladder cancer. Patients will receive neoadjuvant therapy with CDX-1307 plus cisplatin and gemcitabine or cisplatin and gemcitabine alone...